INmune Bio Announces Results of Additional Blinded Interim Analysis of Phase 2 Alzheimer's Disease Trial Demonstrating Correlation between EMACC and CDR-SB EndpointsGlobeNewsWire • Tuesday
INmune Bio Inc. Announces Second Quarter 2024 Results and Provides Business UpdateGlobeNewsWire • 08/01/24
INmune Bio Inc. Announces New Phase 1 Study Data Demonstrating Dose-Dependent Effect of XPro™ on Proteins that Regulation Synapses in Alzheimer's PatientsGlobeNewsWire • 07/29/24
INmune Bio Inc. to Report Second Quarter 2024 Financial Results and Provide a Corporate Update on Thursday, August 1, 2024GlobeNewsWire • 07/25/24
INmune Bio Inc. Publishes Novel Biology on Natural Killer Cancer Immunotherapy INKmune™ in the Journal for ImmunoTherapy of CancerGlobeNewsWire • 07/23/24
INmune Bio: Still A Bargain If Their Alzheimer's Program Reaches Its InflectionSeeking Alpha • 07/05/24
INmune Bio Inc. Announces First Quarter 2024 Results and Provides Business UpdateGlobeNewsWire • 05/09/24
INmune Bio Inc. to Report First Quarter 2024 Financial Results and Provide a Corporate Update on Thursday, May 9GlobeNewsWire • 05/07/24
INmune Bio Inc. Provides Update on Two Patients from the Phase 1b Alzheimer's Disease Trial who Continue to Receive XPro™ Under Compassionate Use for Over Three YearsGlobeNewsWire • 04/30/24
INmune Bio Inc. Completes First Cohort and Initiates Second Cohort of Phase 1/2 Study of INKmune™ Natural Killer Cell Therapy in Patients with Metastatic Castration-Resistant Prostate CancerGlobeNewsWire • 04/29/24
INmune Bio Inc. Announces $9.7 Million Registered Direct Offering Priced At-the-Market Under Nasdaq RulesGlobeNewsWire • 04/25/24
INmune Bio Inc. Announces 24-Month Stability Validation of XPro™ for Phase III Readiness and Commercial Supply Chain Modeling & Development of Novel Immunogenicity AssayGlobeNewsWire • 04/23/24
INmune Bio Inc. Raises Approximately $4.8 Million in Gross Proceeds Through Registered Direct Offering with Officers, Employees and Directors Purchasing Approximately 20% of the OfferingGlobeNewsWire • 04/22/24
INmune Bio Inc. Presents Data on INB03's Role as an Immune Check Point Modulator in the Treatment of High-Risk Breast Cancer at AACR 2024GlobeNewsWire • 04/08/24
INmune Bio Inc. Announces Year End 2023 Results and Provides a Q4 Business UpdateGlobeNewsWire • 03/28/24
INmune Bio Inc. to Report Fourth Quarter 2023 Financial Results and Provide a Corporate Update on Thursday, March 28GlobeNewsWire • 03/26/24
INmune Bio CSO and Co-Founder Mark Lowdell, Ph.D. Receives The ISCT Career Achievement Award in Cell and Gene TherapyGlobeNewsWire • 03/13/24